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Abstract
Infection, coinfection and type-specific human papillomavirus (HPV) distribution was evaluated in human immunodefi-
ciency virus (HIV)-positive women from paired cervical and urine samples. Paired cervical and urine samples (n = 204) were
taken from HIV-positive women for identifying HPV-DNA presence by using polymerase chain reaction (PCR) with three
generic primer sets (GP5+/6+, MY09/11 and pU1M/2R). HPV-positive samples were typed for six high-risk HPV (HR-HPV)
(HPV-16, -18, -31, -33, -45 and -58) and two low-risk (LR-HPV) (HPV-6/11) types. Agreement between paired sample results
and diagnostic performance was evaluated. HPV infection prevalence was 70.6% in cervical and 63.2% in urine samples.
HPV-16 was the most prevalent HPV type in both types of sample (66.7% in cervical samples and 62.0% in urine) followed by
HPV-31(47.2%) in cervical samples and HPV-58 (35.7%) in urine samples. There was 55.4% coinfection (infection by more
than one type of HPV) in cervical samples and 40.2% in urine samples. Abnormal Papanicolau smears were observed in
25.3% of the women, presenting significant association with HPV-DNA being identified in urine samples. There was poor
agreement of cervical and urine sample results in generic and type-specific detection of HPV. Urine samples provided the
best diagnosis when taking cytological findings as reference. In conclusion including urine samples could be a good
strategy for ensuring adherence to screening programs aimed at reducing the impact of cervical cancer, since this sample is
easy to obtain and showed good diagnostic performance.
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Introduction
The human immunodeficiency virus (HIV) is a sexually-
transmitted infection (STD) having a great impact around the
world due to the large amount of people living with such infection
(34.2 million) and the frequent appearance of new cases (2.5
million in 2011) [1]. It is characterized by affecting immune system
CD4+ cells, thereby leading to a reduction in the body’s efficiency
regarding the presentation of a response against other pathogens,
making an individual more vulnerable to other types of infection
[2].
Some studies have suggested that women living with HIV/
AIDS have increased frequency and incidence of single and
multiple infections caused by human papillomavirus (HPV) [3];
the natural history of infection becomes altered, thereby leading to
an increased risk of developing cervical cancer (CC) and
contributing towards this type of cancer being the most frequently
diagnosed in HIV-positive women [4]. This relationship may be
due to: higher HPV exposure in HIV-infected women, increased
frequency of main risk factors involved in CC development or the
role of HIV-related immunosuppression in favoring carcinogenesis
[5].
The immunosuppression can be attenuated through using
antiretroviral therapy which favors balanced counts of CD4
lymphocytes, however, this therapy has not been consistently
implicated in the reduction of HPV-related diseases [6].
The CC incidence in the Colombian general population is 36.4
cases/year/100,000 women [7]; the disease onset occurs approx-
imately between 7 and 12 years after initial HPV infection [8].
These clinical features are altered in women infected simulta-
neously with HPV and HIV where a short-term clinical outcome
usually occurs, involving lesions developing more aggressively,
slower HPV infection regression rates and poorer responses to
treatment [9]; such factors mean that pre-cancerous lesions could
reach 60% (evolving in less than 3 years) [10].
Cervical cytology is the most widely used strategy for reducing
the cervical cancer burden around the world [11]. However, this
screening test has reduced impact in HIV-infected women, as this
group has a greater probability of becoming infected with HPV
and developing cervical lesions [12], which has led to cytological
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screening guidelines being rewritten, now including a test every six
months during the first year followed by a yearly check-up scheme
if no lesions are observed [13]. Nevertheless, cytology coverage in
this group of women is poor and insufficient [10], therefore,
monitoring programs that allow the constant screening in
extended time periods is thus suggested, considering the high risk
associated with this group of women.
In view of the above, the use of complementary techniques to
the Papanicolau test could represent a useful tool in detecting
women at risk. Some of these methods are non-invasive, such as
self-sampling, as when they are used in screening programs they
could provide advantages related to increased acceptance regard-
ing sample-taking, adherence and following-up women, especially
those having some form of immunological compromise [14,15].
Specimen tampons, vaginal swabs and urine samples have been
studied as self-sampling methods; such sampling methods are also
used for detecting other sexually-transmitted pathogens affecting
the cervical area [9,16], urine samples being the easiest to obtain
and having had the greatest acceptance in the population.
However, they do have some limitations, including low cellular
load and they are not taken directly from the HPV infection site;
this could mean that the results obtained from this type of sample
might not reflect the real clinical state of an infection [14].
In spite of their limitations, using urine samples as a test for
detecting HPV-DNA presence could facilitate frequent sample-
taking due to their practicality and greater acceptance among
women. This could be useful in studies involving a large number of
samples and a pelvic examination is also not required, meaning
that sample-taking will not affect the natural history of HPV
infection as there is no risk of micro-lesions being produced, nor
will inflammatory reactions occur [15].
Despite of multiple studies available in the literature that have
evaluated HPV-DNA detection from urine sample [15], a few
number of these have been described the diagnostic performance
of this sample in HIV-positive women population. Furthermore
those who have done it had included a limited number of
individuals [9,17].
In Colombia high prevalence of HPV infection and co-infection
in healthy women population have been reported, using cervical
samples [18,19]. However haven’t be evaluated HPV DNA
detection from urine samples neither in HIV-positive women
population.
This study aimed at identifying the infection, coinfection
(defined here as being infection by more than one type of HPV
simultaneously) and type-specific distribution profile of six high-
risk HPV (HR-HPV) types and two low-risk (LR-HPV) types, from
paired cervical and urine samples of women diagnosed with HIV/
AIDS, confirmed by Western blot. Finally, we evaluated the
diagnostic performance of urine samples compared to cervical
samples for detecting HPV infection.
Materials and Methods
Study population and sample size
HIV-infected women (such infection having been confirmed by
Western blot) participating in cervical cancer screening campaigns
being offered by the Centro de Asistencia Cientı´fica de Alta
Complejidad S.A.S., in Bogota´, Colombia, were included in the
present study. The study was approved and supervised by the
participating institutions’ ethics committees: Fundacio´n Instituto
de Inmunologı´a de Colombia’s ethics committee and Centro
de Asistencia Cientı´fica de Alta Complejidad S.A.S.’ ethics
committee.
Sample size was calculated assuming an estimated 80% HPV
infection rate in HIV-positive women [4,17,20], according to data
reported in the literature. Estimators were calculated using 0.05
precision along with 95% confidence intervals (95%CI) using
STATA9 software sampsi command.
Collecting and processing cervical and urine samples
All the women enrolled in the study were informed about the
research objective; they signed an informed consent form and
filled in a questionnaire to facilitate collecting socio-demographic
data and information regarding their sexual habits and other risk
factors related to acquiring HPV infection.
Each woman’s urine and cervical samples were taken on the
same day; the first sample from a midstream urine specimen was
self-collected, kept at 4uC and processed within 72 hours after
being collected. The second sample taken from cervical cells was
obtained during Papanicolau test, following Colombian obligatory
health plan guidelines regarding cervical cancer detection and
control programs in Colombia [21]; these cells were preserved in
95% ethanol [22,23] and kept at 4uC until being processed. The
histological findings were reported following the Bethesda
classification [13].
The cells were precipitated by spinning at 2,3006 g for
20 minutes at 4uC for urine samples and at 15,0006 g for
10 minutes at 4uC for cervical samples. DNA was extracted from
cell pellets of paired samples using a QuickExtract DNA extraction
kit (Epicentre, Madison, WI), following the manufacturer’s
instructions. Two PCR amplifications were made with specific
primers directed at a segment of the human b-globin constitutive
gene (GH20/PC04 and PC03/PC04) for evaluating DNA
integrity [18,22,24].
Detecting human papillomavirus DNA by PCR
amplification
Samples yielding a positive result for the human b-globin gene
were amplified for detecting HPV using three consensus primer
sets (for detecting more infected women) as it has been reported
that using a single set might lead to underestimating viral
prevalence compared to studies using more than one generic
detection system [25].
Two of the primers sets were directed to the region encoding
late viral protein L1: GP5+/6+ and MY09/11 [26,27]; PCR
conditions have been described previously [22]. A third set of
primers (pU1M/2R) was directed to the HR-HPV E6/E7 region
[28,29]. Assays were run in a final 25 ml volume. The mix
contained 16 amplification buffer, 100 mM of each dNTP,
2.5 mM MgCl2, 1 U MangoTaq DNA polymerase (Bioline,
London, UK) and 1 mM of each primer. The following
amplification profile was used: an initial denaturing step at 94uC
for 10 min, followed by 30 amplification cycles lasting 1 min at
94uC, 2 min at 53uC and 2 min at 72uC, followed by a final
extension step for 7 min at 72uC.
Generic primer sets’ HPV-DNA detection analytical sensitivity
has been reported in previous studies, the detection limit being 102
and 104 plasmid copies in 100 ng HPV-DNA for HPV-16 and -45,
respectively, using a GP5+/6+ primer set [30], 10 HPV copies of
HPV-31 type and 102 HPV copies of HPV-16, -18, -33, -45 and -
58 using an MY09/11 primer set [31] and 0.1 copies of the HPV-
16 genome per cell using a pU1M/2R primer set [28].
Samples which proved positive for any of the three generic
primer sets were amplified by PCR for identifying the six HR-
HPV viral types (HR-HPV-16, -18, -31, -33, -45, -58), using type-
specific primers targeting the E5, E6 and E7 regions, according to
that reported in the literature for each viral type [22,32,33]. Two
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types of LR-HPV were detected (LR-HPV-6/11) [22,34]. The
amplification products were visualized on 2% agarose gels for
human b-globin and the three generic reactions, and on 2.5% gels
for the type-specific reactions. All gels were stained with SYBR
Safe (Invitrogen, Carlsbad, CA).
Statistical analysis
Means and standard deviations were used for describing
continuous variables; categorical variables were expressed in terms
of frequencies and percentages. The frequency of events of interest
was reported together with their corresponding 95% confidence
intervals that were calculated using the bootstrap method. The
association between categorical variables was evaluated with Chi-
square (x2) tests, using a significance level of 0.05.
Agreement between HPV results for urine and cervical samples
was evaluated using the kappa coefficient (k), and its correspond-
ing 95%CI, classified as follows: negative values, as well as values
from 0 to 0.2 = poor, from 0.21 to 0.4 = slight, from 0.41 to
0.6 = fair, from 0.61 to 0.8 = moderate, from 0.81 to 0.99 = sub-
stantial and 1.0 = perfect agreement [27]. The urine HPV tests’
operative characteristics were evaluated for determining sensitiv-
ity, specificity, positive and negative predictive values and receiver
operating characteristic (ROC) area (as the average of sensitivity
and specificity), taking the HPV cervical sample result as
reference. STATA 9 software was used for all statistical analysis.
Results
Socio-demographic data
Two hundred and forty five women between 20 and 73 years
old, were enrolled in the study (mean age: 38.1 years; SD 10.7
years) (Table 1). Two hundred and thirty nine of the 245 cervical
samples (97.6%) were positive by human b-globin amplification
and 208 of the 226 urine samples (92.4%). Fifty one women were
not included in the statistical analysis due to their samples’ low
DNA quality (negative result for b-globin) or a lack of either of the
samples (cervical or urine).
Human papillomavirus prevalence and type-specific
distribution
HPV infection frequency in cervical and urine samples was
70.6% (n = 144; 63.8–73.7 95%CI) and 63.2% (n = 129; 56.2–69.9
95%CI), respectively. Type-specific viral identification revealed
that HPV-16 had the greatest prevalence in both samples, whilst
HPV-31 had the second greatest prevalence in the cervical
samples and HPV-58 in urine samples; the other viral types had a
variable distribution in both samples (Figure 1).
It was found that 55.4% (n = 113; 95% CI = 48.3–62.3) of the
cervical samples had coinfection, compared to 40.2% (n = 82;
33.4–47.3 95%CI) of the urine samples. Regarding a description
of the number of types of HPV simultaneously present in each
sample analyzed, urine samples revealed more uninfected women
or those having just one HPV-type compared to the results
obtained for cervical samples where more coinfections were
detected (2 to 8 types of HPV). The presence of multiple infection
per sample type had a statistically significant relationship (Fisher’s
exact test, p = 0.000) (Figure 2).
Cytological abnormalities and HPV presence
The Papanicolau test gave abnormal cytological findings in
28.9% of the population (n = 56; 95% CI = 22.6–35.8), results
being classified as follows: 10.3% (n = 20) had atypical squamous
cells of undetermined significance (AS-CUS), 16.5% (n = 32) low-
grade squamous intraepithelial lesions (L-SIL) and 2.1% (n = 4)
high-grade squamous intraepithelial lesions (H-SIL).
The HPV infection results obtained from the two samples were
classified according the cytological results; data are shown in
Table 2.
The association between the presence of HPV-DNA in each
sample and the cytological findings (categorized as being normal/
abnormal) revealed that 20.4% (n = 12) of the women having
abnormal cytological findings had a negative result for HPV
infection in the cervical sample while 78.6% gave a positive result
(n = 44). Such difference was not statistically significant
(x2(1) = 2.69; p = 0.101). On the other hand, it was found that
19.6% (n = 11) of the samples having abnormal cytological
findings had negative test for HPV-DNA in the urine sample,
Table 1. Description of the socio-demographic characteristics
of the female population enrolled in the study.
Characteristic Categories n (%)*
Age, years (201) 20–34 91 (45.3)
35–49 72 (35.8)
$50 38 (18.9)
Ethnicity (197) White 132 (67.0)
Indigenous 3 (1.5)
Mestizo 58 (29.5)
Black 4 (2.0)
Marital status (186) Single 52 (27.9)
Married 24 (12.9)
Common law marriage 60 (32.3)
Separated 21 (11.3)
Widowed 29 (15.6)
Age at first intercourse (195) ,18 118 (60.5)
$18 77 (39.5)
Pregnancies (192) None 9 (4.7)
1 45 (23.4)
2 51 (26.6)
3 47 (24.5)
$4 40 (20.8)
Life time number of sexual
partners (194)
1 30 (15.5)
2 48 (24.7)
3 43 (22.2)
$4 73 (37.6)
Contraceptive method** (165) None 33 (20.0)
Hormonal
contraceptives
5 (3.0)
Intrauterine device 11 (6.7)
Surgery 35 (21.2)
Condom 54 (32.7)
Condom + other 27 (16.4)
Smoking status (193) No 163 (84.5)
Yes 30 (15.5)
*Categories have a size lower than 204, given that data was missing from the
surveys.
**Contraceptive method used at the moment of enrollment in this study.
doi:10.1371/journal.pone.0056509.t001
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Figure 1. Prevalence of HPV types in cervical and urine samples for 204 HIV-infected Colombian women.
doi:10.1371/journal.pone.0056509.g001
Figure 2. Number of HPV types in cervical and urine samples
for 204 HIV-infected Colombian women.
doi:10.1371/journal.pone.0056509.g002
Table 2. HPV detection in both sample sources according to
the cytological results.
HPV detection n (%)
Both
positive
Cytology
only Urine only
Both
negative Total (194)
Normal 57 (41.3) 35 (25.4) 22 (15.9) 24 (17.4) 138
ASC-US 12 (60.0) 4 (20.0) 3 (15.0) 1 (5.0) 20
L-SIL 24 (75.0) 1 (3.1) 3 (9.4) 4 (12.5) 32
H-SIL 2 (50.0) 1 (25.0) 1 (25.0) 0 (0.0) 4
The percentages show the frequency of women that tested positive with
respect to the total per row. AS-CUS: Atypical squamous cells of undetermined
significance. H-SIL: high-grade squamous intraepithelial lesions. L-SIL: Low-
grade squamous intraepithelial lesions.
doi:10.1371/journal.pone.0056509.t002
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compared to 80.4% (n = 45) where viral DNA was detected; this
trend was statistically significant (x2(1) = 9.22; p = 0.002).
Agreement between both samples and clinical
performance
The results obtained for infection (generic and type-specific) in
both samples (cervical and urine) were compared to cytological
findings, categorizing the population as normal or abnormal
(Tables 3-A and 3-B, respectively), where the generic identification
of HPV-DNA, showed the greatest percentage agreement.
Agreement between paired samples showed that generic viral
detection had greater than 50% agreement in the results obtained
for the three sets of primers used, while greater agreement was
found for HPV-33 and HPV-45 types for type-specific identifica-
tion (even though these were the least prevalent in the population
being studied). However, the k values gave poor correlation in all
cases (Figure 3).
The urine sample’s diagnostic performance revealed 68.8%
sensitivity (60.5–76.2 95%CI), 50% specificity (36.8–63.2 95%CI),
76.7% positive predictive value (PPV) (68.5–83.7 95%CI), 40%
negative predictive value (NPV) (28.9–52 95%CI) and a 0.59
ROC area (0.52–0.67 95%CI).
Discussion
Developing cervical cancer has been related to factors
determining its progression, including the type of HPV infection,
viral load and persistence of the infection [35]. Nevertheless, as
most women have an efficient immune system they can manage to
rid themselves of infection within a period of less than two years
[36].
However, when immune system activity becomes compromised,
as in HIV-positive women, the elimination of concomitant
infection is less efficient; a clear example lies in that described
for women suffering simultaneous HIV-HPV infection whose
natural history of infection becomes altered, thereby leading to the
appearance of cervical lesions in less time. This is related to a
reduction in HPV elimination rates, greater efficiency regarding
the cellular transformation of all viral types and lower lesion
regression rates [4].
According to the data obtained in this study, DNA integrity
confirmed by amplifying two segments of the human b–globin
gene (as an indirect measurement method) revealed that the
percentage of samples having degraded or non-amplifiable DNA
were low in both cervical and urine samples, thereby highlighting
that the latter also represents a good source of DNA for amplifying
specific targets using molecular biology techniques and could thus
be considered as a useful cervical screening tool (in spite of 30%
inhibition having been reported for such amplification) [37,38].
The frequency of HPV infection detected in the present
population agreed with that reported in previous studies carried
out on populations having similar characteristics, such as that
reported by Ferenczy et al., who described 73.6% crude HPV
infection prevalence from cervical samples taken from sexually-
active HIV-positive women [3]. Nevertheless, HPV infection
prevalence in urine in the present study was lower than that in
cervical samples; similar data have been reported previously for
this type of sample [39]. Such difference in viral detection
percentage could have been related to the low number of
exfoliated cervical cells present in urine, to the presence of PCR
inhibitors in this sample [37] or to methodological issues related
with sampling strategies, storage conditions, sample manipulation
and DNA extraction method that could affect the HPV-DNA
detection [15]; therefore is necessary to continue working on the
improvement of protocols for HPV-DNA detection from urine
sample.
Regarding type-specific distribution, the data obtained from
cervical samples agreed with published reports concerning the
general Colombian population, HPV-16 being the most prevalent
type, followed by HPV-31 [18]. However, urine samples’ type-
specific distribution profile revealed some differences compared to
that for the cervical samples, HPV-18 being the second most
prevalent type, this being similar to worldwide data reported in the
pertinent literature [40]. It was also found that HPV-58 and HPV-
45 were the only two viral types more prevalent in urine samples
than in cervical samples, which could have been related to the fact
that some viral types may preferentially infect the vagina’s
keratinized tissue than the non-keratinized tissue of the cervix
[41]; however, more research needs to be done into HPV infection
profiles regarding different areas of the lower genital tract.
Table 3. HPV detection and type-specific distribution from each source sample (cervical and urine) in the group of women having
normal and abnormal cytological findings.
Women having a normal cytology result (n = 138) Women having an abnormal cytology result (n = 56)
n (%) n (%)
Both positive
Cervical sample
only
Urine sample
only Both negative Both positive
Cervical sample
only
Urine sample
only Both negative
HPV infection* 57 ( 41.3 ) 35 ( 25.4 ) 22 ( 15.9 ) 24 ( 17.4 ) 38 ( 67.9 ) 6 ( 10.7 ) 7 ( 12.5 ) 5 ( 8.9 )
HPV-16 23 ( 20.2 ) 41 ( 36.0 ) 22 ( 19.3 ) 28 ( 24.5 ) 14 ( 27.5 ) 12 ( 23.5 ) 17 ( 33.3 ) 8 ( 15.7 )
HPV-18 6 ( 5.3 ) 33 ( 28.9 ) 19 ( 16.7 ) 56 ( 49.1 ) 6 ( 11.8 ) 12 ( 23.5 ) 10 ( 19.6 ) 23 ( 45.1 )
HPV-31 7 ( 6.1 ) 31 ( 27.2 ) 17 ( 14.9 ) 59 ( 51.8 ) 5 ( 9.8 ) 21 ( 41.2 ) 9 ( 17.6 ) 16 ( 31.4 )
HPV-33 4 ( 3.5 ) 20 ( 17.6 ) 12 ( 10.5 ) 78 ( 68.4 ) 5 ( 9.8 ) 11 ( 21.6 ) 3 ( 5.9 ) 32 ( 62.7 )
HPV-45 0 ( 0.0 ) 7 ( 6.2 ) 12 ( 10.5 ) 95 ( 83.3 ) 1 ( 2.0 ) 7 ( 13.7 ) 10 ( 19.6 ) 33 ( 64.7 )
HPV-58 4 ( 3.5 ) 20 ( 17.5 ) 22 ( 19.3 ) 68 ( 59.7 ) 6 ( 11.8 ) 9 ( 17.6 ) 13 ( 25.5 ) 23 ( 45.1 )
HPV-6/11 2 ( 1.8 ) 20 ( 17.5 ) 14 ( 12.3 ) 78 ( 68.4 ) 5 ( 9.8 ) 13 ( 25.5 ) 2 ( 3.9 ) 31 ( 60.8 )
*The positivity percentage for HPV infection (using generic primers) in each sample source. Type-specific identification was used in some HPV infection-positive women
regarding any of the sample sources (n = 114 and n = 51 for the groups of women having normal or abnormal cytology result, respectively).
doi:10.1371/journal.pone.0056509.t003
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In addition, the variations in HPV type-specific distribution
profile could have been related to the presence of HIV infection as
it has been described that such distribution in immunologically-
compromised women could vary; moreover, it has been described
that such incidence is 16 times higher in the immunologically-
compromised group than that found in immunologically-compe-
tent women [3]. An additional explanation for the different viral
type distribution between samples could be attributable to a
varying exfoliation pattern in cells infected with each viral type,
however, it has not yet been established whether exfoliated cells in
urine are influenced by viral infection type or the state of infection
[15].
Coinfection was found in both urine and cervical samples in
around half the study population; this could have been attributed
to the low infection elimination rate allowing different viral types
to settle in the cervical epithelium; multiple infection events could
have been also due to the reduced systemic and local cell immunity
found in HIV-positive women [12].
There was poor agreement between generic and type-specific
identification results; this may have been related to the samples’
different nature, as well as HPV tropism for cervical epithelium. A
lower number of viral copies in urine are expected regarding
cervical samples, as the latter would have been taken from the
pathogen’s direct localization site.
Interestingly, the test involving self-collected urine samples had
greater sensitivity (68.8% in this study vs. 55.3%) and more
specificity (50.0% in this study vs. 44.9%) for detecting HPV-DNA
compared with a previous study using the same identification
protocol [19], which could indicate a potential use for the clinical
application of this sample source. Nevertheless, additional studies
must be carried out in the general population for determining
clinical applicability, storage conditions, suitable extraction
method, the most appropriate urine fraction to be used in the
molecular analysis, and other factors that could affect the
diagnostic performance of this sample source.
Developing strategies in cervical cancer control and prevention
programs will be particularly determinant in contributing towards
increasing coverage, sample taking, adherence and follow-up of
women, mainly those presenting some type of immunosuppres-
sion. According to the results obtained here, self-sampling
methods, such as urine sampling, could be taken into account as
useful tools for preventing this pathology, since they offer good
diagnostic performance and greater acceptability among women.
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